ConductScience.org, home

Paper329987

Phase I anti-cancer agents: vindesine (desacetyl vinblastine amide sulfate).

Dyke RW and 1 other. Cancer Treat Rev, 1977. Cited by 102 papers, by iCite.

Cite this record

ConductScience Library. Phase I anti-cancer agents: vindesine (desacetyl vinblastine amide sulfate). Papers, record 329987. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/329987

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Phase I anti-cancer agents: vindesine (desacetyl vinblastine amide sulfate).
PubMed
Journal
Cancer Treat Rev
PubMed
Year
1977
PubMed
Publication types
Clinical Trial, Comparative Study, Journal Article, Review
PubMed
Citations, by iCite
102
iCite
Relative citation ratio, by iCite
4.96
iCite
Revised in PubMed
2019-10-21
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Dyke RWR W
2Nelson RLR L

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NeoplasmsMajor topic
VinblastineMajor topic
Animals
Clinical Trials as Topic
Female
Humans
Kinetics
Male
Melanoma
Neoplasms, Experimental
Vincristine

Source PubMed

Download CSV of topics

Cited by22

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 102 citations.

PMIDTitleJournalYearIn PapersSource
8306418Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinleucinol in mice as determined by high-performance liquid chromatography.Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/8306418PubMed
8262726Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography.Invest New Drugs1993https://conductscience.org/library/papers/8262726PubMed
8262725Is there a role for vindesine in the treatment of non-small cell lung cancer?Invest New Drugs1993https://conductscience.org/library/papers/8262725PubMed
7460196Phase I evaluation of divided-dose vinblastine sulfate.Cancer Chemother Pharmacol1980https://conductscience.org/library/papers/7460196PubMed
7326201Biochemical effects of vindesine.Br J Cancer1981https://conductscience.org/library/papers/7326201PubMed
7307235Neurological toxicity of vindesine used in combination chemotherapy of 51 human solid tumors.Cancer Chemother Pharmacol1981https://conductscience.org/library/papers/7307235PubMed
7296754Experimental in vivo cross-resistance of vinca alkaloid drugs.Cancer Chemother Pharmacol1981https://conductscience.org/library/papers/7296754PubMed
6678881Vindesine in head and neck cancer. A Southwest Oncology Group Phase II pilot study.Invest New Drugs1983https://conductscience.org/library/papers/6678881PubMed
6381742Cancer chemotherapy: past, present, and future--Part I.J Natl Med Assoc1984https://conductscience.org/library/papers/6381742PubMed
4041363Cytotoxicity of etretinate and vindesine.Br J Cancer1985https://conductscience.org/library/papers/4041363PubMed
3390658Comparative uptake, retention and action of vincristine, vinblastine and vindesine on murine leukaemic lymphoblasts sensitive and resistant to vincristine.Br J Pharmacol1988https://conductscience.org/library/papers/3390658PubMed
2384117In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. I. Vindesine (4-deacetyl-vinblastine 3-carboxyamide).Eur J Drug Metab Pharmacokinet1990https://conductscience.org/library/papers/2384117PubMed
2254384Long-term application of vindesine: toxicity and tolerance.J Cancer Res Clin Oncol1990https://conductscience.org/library/papers/2254384PubMed
2191847Antineoplastic drugs in 1990. A review (Part II).Drugs1990https://conductscience.org/library/papers/2191847PubMed
455587Vindesine. A review of phase-II trials.Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/455587PubMed
455586Phase II evaluation of vindesine in the treatment of colorectal and esophageal tumors.Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/455586PubMed
455585Vindesine in the treatment of breast cancer.Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/455585PubMed
455584Vindesine as a single agent in the treatment of advanced malignant melanoma.Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/455584PubMed
455583Clinical pharmacokinetics of vindesine.Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/455583PubMed
455582Correlation of the clinical neurotoxicity of the vinca alkaloids vincristine, vinblastine, and vindesine with their effects on cultured rat midbrain cells.Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/455582PubMed

See all 22 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/329987

GET https://conductscience.org/api/papers/v1/329987/cited_by?page=2